Related Experiment Video
Updated: Aug 7, 2026
08:13
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy
Hidemi Kajimoto1, Keiko Ishigaki, Kenichi Okumura
1Department of Pediatric Cardiology, Tokyo Women's Medical University, Japan.
Summary
Combination therapy with carvedilol and an angiotensin-converting enzyme inhibitor (ACEI) significantly improves left ventricular systolic function in muscular dystrophy patients. This treatment offers a promising approach to managing cardiac complications in this population.
Area of Science:
- Cardiology
- Neuromuscular Disorders
- Pharmacology
Background:
- Cardiac dysfunction is a progressive complication in muscular dystrophy, leading to heart failure and mortality.
- Standard heart failure treatments like angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers are effective in adults, but their use in muscular dystrophy patients is not well-established.
Purpose of the Study:
- To investigate the efficacy of carvedilol, a beta-blocker, and/or ACEI in improving ventricular function in patients with muscular dystrophy.
- To compare the effects of combination therapy versus ACEI monotherapy on cardiac parameters in this patient group.
Main Methods:
- A study involving 28 muscular dystrophy patients (Duchenne, Fukuyama, Emery-Dreifuss) divided into two groups.
- Group 1 (13 patients) received carvedilol plus an ACEI; Group 2 (15 patients) received ACEI only.
- Echocardiographic assessment of left ventricular parameters, including left ventricular fractional shortening (LVFS), was conducted over a 2-3 year follow-up period.
Main Results:
- Combination therapy with carvedilol and an ACEI for 2 years led to a significant increase in left ventricular fractional shortening (LVFS).
- Patients receiving only ACEI showed no significant change in LVFS.
- Left ventricular end-diastolic dimension increased in the ACEI-only group but remained stable in the carvedilol combination therapy group.
Conclusions:
- The combination of carvedilol and an ACEI demonstrates a significant benefit in improving left ventricular systolic function in patients with muscular dystrophy.
- This combination therapy appears to be a beneficial strategy for managing cardiac function in muscular dystrophy.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...